U.S. patent application number 16/402315 was filed with the patent office on 2019-08-22 for small molecule inhibitors of botulinum neurotoxins.
This patent application is currently assigned to THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR. The applicant listed for this patent is THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR. Invention is credited to JOHN H. CARDELLINA, II, SIVANESAN DAKSHANAMURTHY, SUSAN M. ENSEL, ISTVAN J. ENYEDY, NIZAMETTIN GUL, VIRGINIA I. ROXAS-DUNCAN, SALIMUDDIN SHAH, LEONARD A. SMITH, REBECCA C. VIEIRA, DAVID C.H. YANG.
Application Number | 20190256471 16/402315 |
Document ID | / |
Family ID | 41417060 |
Filed Date | 2019-08-22 |
![](/patent/app/20190256471/US20190256471A1-20190822-C00001.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00002.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00003.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00004.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00005.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00006.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00007.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00008.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00009.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00010.png)
![](/patent/app/20190256471/US20190256471A1-20190822-C00011.png)
View All Diagrams
United States Patent
Application |
20190256471 |
Kind Code |
A1 |
ROXAS-DUNCAN; VIRGINIA I. ;
et al. |
August 22, 2019 |
SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS
Abstract
The invention provides potent quinolinol-based BoNT/A
small-molecule inhibitors of botulinum neurotoxins, in particular
of Clostridium botulinum serotype A neurotoxins. The invention also
provides methods of using these small-molecule inhibitors to
inhibit infections by Clostridium botulinum, as well as, methods of
preventing infections by Clostridium botulinum through materials
that may be ingested.
Inventors: |
ROXAS-DUNCAN; VIRGINIA I.;
(FORT DETRICK, MD) ; SMITH; LEONARD A.; (FORT
DETRICK, MD) ; GUL; NIZAMETTIN; (FORT DETRICK,
MD) ; CARDELLINA, II; JOHN H.; (FORT DETRICK, MD)
; VIEIRA; REBECCA C.; (FORT DETRICK, MD) ; ENSEL;
SUSAN M.; (FORT DETRICK, MD) ; YANG; DAVID C.H.;
(WASHINGTON, DC) ; ENYEDY; ISTVAN J.; (WASHINGTON,
DC) ; DAKSHANAMURTHY; SIVANESAN; (WASHINGTON, DC)
; SHAH; SALIMUDDIN; (WASHINGTON, DC) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY
OF THE AR |
FORT DETRICK |
MD |
US |
|
|
Assignee: |
THE GOVERNMENT OF THE UNITED STATES
AS REPRESENTED BY THE SECRETARY OF THE AR
FORT DETRICK
MD
|
Family ID: |
41417060 |
Appl. No.: |
16/402315 |
Filed: |
May 3, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13058764 |
Aug 22, 2011 |
10301265 |
|
|
PCT/US2009/045546 |
May 28, 2009 |
|
|
|
16402315 |
|
|
|
|
61056664 |
May 28, 2008 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 215/26 20130101;
C07D 401/12 20130101; C07D 215/40 20130101; A61P 25/00 20180101;
A61P 31/04 20180101 |
International
Class: |
C07D 215/26 20060101
C07D215/26; C07D 215/40 20060101 C07D215/40; C07D 401/12 20060101
C07D401/12 |
Claims
1. A composition having Formula 1: ##STR00050## wherein R.sub.1,
R.sub.2, and R.sub.3, being the same or different, are each
selected from the group consisting of a H, a C.sub.1 to C6 straight
or branched alkyl group, an aryl group, a halogen, NR.sub.5R.sub.6,
NO.sub.2, CH.sub.2 CH.sub.2OH, CHO, COOH, CN, SO.sub.3H, and
SO.sub.2NR.sub.7R.sub.8; wherein R.sub.5, R.sub.6, R.sub.7 and
R.sub.8 being the same or different, are each selected from the
group consisting of a H, a C.sub.1 to C.sub.6 straight or branched
alkyl group, and an aryl group; wherein R.sub.4 is selected from
the group consisting of a straight or branched alkyl group and an
aryl group; wherein Ar.sub.1 is selected from the group consisting
of 5- or 6-membered aromatic rings, 5- or 6-membered heteroaromatic
rings, polycyclic aromatic ring systems, and heteroaromatic ring
systems; wherein X is selected from the group consisting of a O,
OCH.sub.2, S, SCH.sub.2, NR.sub.9, NR.sub.9CH.sub.2, NR.sub.9CO,
and CH.sub.2; and wherein R.sub.9 is selected from the group
consisting of a H, a C.sub.1 to C.sub.6 straight or branched alkyl
group, and an aryl group.
2. The composition of claim 1 wherein the halogen is selected from
the group consisting of F, Cl, Br, and I.
3. The composition of claim 1 wherein the aryl group is a phenyl,
biphenyl, thiophenyl, or indolyl ring.
4. The composition of claim 1 further comprising a pharmaceutically
acceptable carrier, excipient, diluent, or adjuvant.
5. The composition of claim 1, which further includes a
pharmaceutically acceptable salt of the compound of Formula 1.
6. A method of inhibiting a botulinum neurotoxin in a subject
comprising administering to the subject a composition comprising at
least one compound of Formula 1 ##STR00051## wherein R.sub.1,
R.sub.2, and R.sub.3, being the same or different, are each
selected from the group consisting of a H, a C.sub.1 to C.sub.6
straight or branched alkyl group, an aryl group, a halogen,
NR.sub.5R.sub.6, NO.sub.2, CH.sub.2OH, CHO, COOH, CN, SO.sub.3H,
and SO.sub.2NR.sub.7R.sub.8; wherein R.sub.5, R.sub.6, R.sub.7, and
R.sub.8, being the same or different, are each selected from the
group consisting of a H, a C.sub.1 to C.sub.6 straight or branched
alkyl group, and an aryl group; wherein R.sub.4 is selected from
the group consisting of a straight or branched alkyl group and an
aryl group; wherein Ar.sub.1 is selected from the group consisting
of 5- or 6-membered aromatic rings, 5- or 6-membered heteroaromatic
rings, polycyclic aromatic ring systems, and heteroaromatic ring
systems; wherein X is selected from the group consisting of a O,
OCH.sub.2, S, SCH.sub.2, NR.sub.9, NR.sub.9CH.sub.2, NR.sub.9CO,
and CH.sub.2; and wherein R.sub.9 is selected from the group
consisting of a H, a C.sub.1 to C.sub.6 straight or branched alkyl
group, and an aryl group.
7. The method of claim 6 wherein the composition includes two or
more compounds of Formula 1.
8. The method of claim 6 wherein the composition includes a
pharmaceutically acceptable salt of a compound of Formula 1.
9. The method of claim 6 wherein the composition further comprises
a pharmaceutically acceptable carrier, excipient, diluent, or
adjuvant.
10. The method of claim 6 wherein the botulinum neurotoxin is a
Clostridium botulinum serotype A neurotoxin, and inhibiting the
botulinum neurotoxin inhibits or prevents a Clostridium botulinum
infection.
11. The method of claim 6 wherein the subject is an animal.
12. The method of claim 6 wherein the subject is a human.
13. A kit for treating a subject exposed to a botulinum neurotoxin
comprising a composition with at least one compound of Formula 1 in
a container, and instruction on administering the at least one
compound, wherein Formula 1 comprises ##STR00052## wherein R.sub.1,
R.sub.2, and R.sub.3, being the same or different, are each
selected from the group consisting of a H, a C.sub.1 to C6 straight
or branched alkyl group, an aryl group, a halogen, NR.sub.5R.sub.6,
NO.sub.2, CH.sub.2 CH.sub.2OH, CHO, COOH, CN, SO.sub.3H, and
SO.sub.2NR.sub.7R.sub.8; wherein R.sub.5, R.sub.6, R.sub.7 and
R.sub.8 being the same or different, are each selected from the
group consisting of a H, a C.sub.1 to C.sub.6 straight or branched
alkyl group, and an aryl group; wherein R.sub.4 is selected from
the group consisting of a straight or branched alkyl group and an
aryl group; wherein Ar.sub.1 is selected from the group consisting
of 5- or 6-membered aromatic rings, 5- or 6-membered heteroaromatic
rings, polycyclic aromatic ring systems, and heteroaromatic ring
systems; wherein X is selected from the group consisting of a O,
OCH.sub.2, S, SCH.sub.2, NR.sub.9, NR.sub.9CH.sub.2, NR.sub.9CO,
and CH.sub.2; and wherein R.sub.9 is selected from the group
consisting of a H, a C.sub.1 to C.sub.6 straight or branched alkyl
group, and an aryl group.
14. A composition having Formula 2 ##STR00053## wherein X is
selected from the group consisting of a O, S, Se, and NH; wherein Y
is selected from the group consisting of a CH or N; wherein
Ar.sub.1 is selected from the group consisting of a monocyclic or
bicyclic aromatic or heteroaromatic ring system, a biphenyl or
bipyridyl ring system, a bridged biphenyl or bipyridyl ring system,
wherein any ring system may be further substituted by one or more
substitution selected from the group consisting of a halogen,
NR.sub.1R.sub.2, OR.sub.3, SO.sub.2NR.sub.4R.sub.5, SR.sub.6, and
R.sub.7; and wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6 and R.sub.7, being the same or different, are each selected
from the group consisting of H, a C.sub.1 to C.sub.6 straight or
branched chain or cycloalkyl ring, a C.sub.1 to C.sub.6 straight or
branched chain acyl group, and an aryl group.
15. A method of inhibiting a botulinum neurotoxin in a subject
comprising administering to the subject a composition comprising at
least one compound of Formula 2 ##STR00054## wherein X is selected
from the group consisting of a O, S, Se, and NH; wherein Y is
selected from the group consisting of a CH or N; wherein Ar.sub.1
is selected from the group consisting of a monocyclic or bicyclic
aromatic or heteroaromatic ring system, a biphenyl or bipyridyl
ring system, a bridged biphenyl or bipyridyl ring system, wherein
any ring system may be further substituted by one or more
substitution selected from the group consisting of a halogen,
NR.sub.1R.sub.2, OR.sub.3, SO.sub.2NR.sub.4R.sub.5, SR.sub.6, and
R.sub.7; and wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6 and R.sub.7, being the same or different, are each selected
from the group consisting of H, a C.sub.1 to C.sub.6 straight or
branched chain or cycloalkyl ring, a C.sub.1 to C.sub.6 straight or
branched chain acyl group, and an aryl group.
16. The method of claim 15 wherein the botulinum neurotoxin is a
Clostridium botulinum serotype A neurotoxin, and inhibiting the
botulinum neurotoxin inhibits or prevents a Clostridium botulinum
infection.
17. The method of claim 15, wherein the composition includes two or
more compounds of Formula 2.
18. The method of claim 15, wherein the composition includes a
pharmaceutically acceptable salt of a compound of Formula 2.
19. The method of claim 15, wherein the composition further
comprises a pharmaceutically acceptable carrier, excipient,
diluent, or adjuvant.
20. A kit for treating a subject exposed to a botulinum neurotoxin
comprising a composition with at least one compound of Formula 2 in
a container, and instruction on administering the at least one
compound, wherein Formula 2 comprises ##STR00055## wherein X is
selected from the group consisting of a O, S, Se, and NH; wherein Y
is selected from the group consisting of a CH or N; wherein
Ar.sub.1 is selected from the group consisting of a monocyclic or
bicyclic aromatic or heteroaromatic ring system, a biphenyl or
bipyridyl ring system, a bridged biphenyl or bipyridyl ring system,
wherein any ring system may be further substituted by one or more
substitution selected from the group consisting of a halogen,
NR.sub.1R.sub.2, OR.sub.3, SO.sub.2NR.sub.4R.sub.5, SR.sub.6, and
R.sub.7; and wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6 and R.sub.7, being the same or different, are each selected
from the group consisting of H, a C.sub.1 to C.sub.6 straight or
branched chain or cycloalkyl ring, a C.sub.1 to C.sub.6 straight or
branched chain acyl group, and an aryl group.
Description
RELATED APPLICATIONS
[0001] This application relates to and claims priority to U.S.
Provisional Patent Application No. 61/056,664, which was filed May
28, 2008, is commonly owned, and is incorporated herein by
reference in its entirety.
SEQUENCE LISTING
[0002] This application contains a sequence listing in paper format
and in computer readable format, the teachings and content of which
are incorporated by reference.
BACKGROUND OF THE INVENTION
Field of the Invention
[0003] The present invention relates to methods and compositions
for inhibiting botulinum neurotoxins. Specifically, the invention
provides quinolinol-based compositions and methods of using
quinolinol-based compositions to inhibit the toxic effects of
serotype A Clostridium botulinum neurotoxins.
Description of the Related Art
[0004] Botulinum neurotoxins (BoNTs), produced by the anaerobic,
Gram-positive bacteria Clostridium botulinum, C. baratii, and C.
butyricum, consist of seven immunologically distinct serotypes
(types A-G). Botulinum neurotoxins are synthesized as
.about.150-kDa single-chain protoxins that are post-translationally
processed by proteolytic cleavage to form a disulfide-linked dimer
composed of a 100-kDa heavy chain (HC) and a 50-kDa light chain
(LC) (27, 31, 35, 36). The HC comprises a 50-kDa C-terminal domain
(Hc) that participates in the binding of toxin to productive
ectoacceptors on the cell surface of peripheral cholinergic nerve
cells (3). Toxin is taken up into the cell by receptor-mediated
endocytosis (4) and the 50-kDa N-terminal domain (Hn) of the HC
facilitates the translocation of the LC across an endosomal
membrane into the cytosol of the nerve cell (30). The LC is a
zinc-dependent endopeptidase that cleaves and inactivates SNARE
(soluble N-ethylmaleimide-sensitive factor attachment protein
receptor) proteins: SNAP-25, VAMP/synaptobrevin, and syntaxin (31,
36). SNARE proteins are essential for exocytosis of
neurotransmitter, and cleavage of SNARE protein(s) by BoNT inhibits
the release of acetylcholine from synaptic terminals leading to
neuromuscular paralysis or botulism (31, 35).
[0005] Worldwide, about 1000 cases of human BoNT poisoning,
predominantly caused by serotypes A and B, are reported yearly
(17). In spite of advances in food production and storage/handling
processes, cases of food-borne botulism persist, including a
massive outbreak in Thailand (26) and the recent US botulism scare
associated with canned chili and other products (2, 28).
[0006] Therapy for botulism consists of immunological intervention
to neutralize and clear toxin from the circulation, and supportive
care, which may include intubation and ventilatory assistance.
However, while antibody therapy can be very effective, it has
several limitations, including limited availability, lot-to-lot
potency variability and short window of application. Clearly, there
is a need for improved therapies and compounds.
[0007] Since small-molecules can be potentially used to treat pre-
and post-exposure BoNT intoxication, research efforts to identify
these antagonists have dramatically increased in recent years.
However, the discovery and development of BoNT serotype A (BoNT/A)
small-molecule inhibitors have long challenged researchers. Part of
the difficulty in this endeavor can be attributed to the unusually
large peptide substrate-enzyme interface (8) that requires a
small-molecule with high affinity to effectively block substrate
binding (47). Moreover, the BoNT toxin and its domains show
considerable conformational flexibility, making design of effective
inhibitors complicated. Despite these challenges, a number of
papers have been published on the initial steps to discover and
develop inhibitors of BoNT/A protease activity using different
approaches. Using high throughput screening of the NCI Diversity
Set, as well as a series of 4-aminoquinolines, Burnett et al. (11)
identified several small-molecule inhibitors of BoNT/A, from which
a common pharmacophore was predicted using molecular modeling (9).
Similarly, a high throughput screen of a library of hydroxamates
(6) resulted in the selection of 4-dichlorocinnamic hydroxamate as
a lead structure for further development (5). Capkova et al. (12)
structurally modified 2, 4-dichlorocinnamic acid hydroxamate to
improve its potency. On the other hand, a computational screen of
2.5 million compounds resulted in the identification of an
inhibitor with a K.sub.i of 12 .mu.M (32), but this value was later
invalidated (47). Computer-aided optimization of this inhibitor
resulted in an analog that showed a two-fold improvement in
inhibitory potency and displayed competitive kinetics by chelating
the active site zinc atom (47).
[0008] Though the above approaches have resulted in the
identification of a number of small-molecule BoNT/A inhibitors, no
compound has yet advanced to pre-clinical development. The majority
of these leads have only been demonstrated to be effective in
enzymatic assays (11, 12, 29, 32, 47). Only a few small-molecules
have been tested in cell-based assays (5, 9, 15) that involved
mixing the compound with the toxin, and not by pre-loading the
inhibitor. To date, none of the recently-identified BoNT/A
inhibitors has been tested in a tissue-based system, and to date
only two compounds were reported to have minimal in vivo activity
(15).
[0009] Herein, are provided the identification of potent
quinolinol-based BoNT/A small-molecule inhibitors using an
integrated strategy that combined in silico screening and
successive biochemical tests, including enzymatic (HPLC-based),
cell-based, and tissue-based assays.
SUMMARY OF THE INVENTION
[0010] The invention provides compositions for inhibiting botulinum
neurotoxins, preferably a neurotoxin associated with Clostridium
botulinum serotype A. The invention also provides methods of using
these compositions to inhibit botulinum neurotoxins and of treating
a subject exposed to botulinum neurotoxins.
[0011] Compositions of the invention comprise Formula 1,
pharmaceutically acceptable salts of Formula 1, or combinations
thereof. Formula 1 is
##STR00001##
wherein R.sub.1, R.sub.2, and R.sub.3, being the same or different,
are each selected from the group consisting of a H, a C.sub.1 to
C.sub.6 straight or branched alkyl group, an aryl group, a halogen,
NR.sub.5R.sub.6, NO.sub.2, CH.sub.2OH, CHO, COOH, CN, SO.sub.3H,
and SO.sub.2NR.sub.7R.sub.8; wherein R.sub.5, R.sub.6, R.sub.7, and
R.sub.8, being the same or different, are each selected from the
group consisting of a H, a C.sub.1 to C.sub.6 straight or branched
alkyl group, and an aryl group; wherein R.sub.4 is selected from
the group consisting of a straight or branched alkyl group and an
aryl group; wherein Art is selected from the group consisting of a
5- and 6-membered aromatic and heteroaromatic rings and polycyclic
aromatic and heteroaromatic ring systems; wherein X is selected
from the group consisting of a O, OCH.sub.2, S, SCH.sub.2,
NR.sub.9, NR.sub.9CH.sub.2, NR.sub.9CO, and CH.sub.2; and wherein
R.sub.9 is selected from the group consisting of a H, a C.sub.1 to
C.sub.6 straight or branched alkyl group, and an aryl group.
[0012] Claimed compositions of the invention exclude known
compounds, for example the known compounds listed in Tables 1 and 2
herein are not claimed as compositions of the invention. Previously
unknown analogs of the compounds listed in Tables 1 and 2 that
inhibit botulinum neurotoxins are within the scope of the
invention. Exemplary analogs are provided in Table 3. Preferably
the compositions of the invention have little or no toxicity to a
subject exposed to the compositions.
[0013] Suitable halogens for inclusion in the invention, alone or
in combination, are chloro (Cl), fluoro (F), bromo (Br), and iodo
(I).
[0014] Preferred aryl groups for inclusion in the invention, alone
or in combination, are phenyl, pyridyl, thiophenyl, furyl, or
indolyl rings.
[0015] An aspect of the invention is that compositions of the
invention may include a pharmaceutically acceptable carrier,
excipient, diluent, or adjuvant.
[0016] The invention also provides methods of using compositions
comprising Formula 1, pharmaceutically acceptable salts of Formula
I, or combinations thereof. Specifically, the invention provides
methods of inhibiting a botulinum neurotoxin in a subject by
administering to the subject a composition comprising at least one
compound, or pharmaceutically acceptable salt, of Formula 1.
Compositions of the invention may be administered alone or as part
of a therapy to treat botulism, i.e. an infection by C.
botulinum.
[0017] In another aspect of the invention, the methods of the
invention may be used to inhibit or prevent a C. botulinum
infection, in particular a C. botulinum serotype A infection, by
admixing one or more compositions of Formula 1, or a
pharmaceutically acceptable salt thereof, with a substance
suspected of including or being exposed to C. botulinum prior to
such substance being ingested by a subject or such substance
contacting another substance that is expected to be ingested by a
subject.
[0018] In another aspect, compositions of the invention comprise
Formula 2, pharmaceutically acceptable salts of Formula 2, or
combinations thereof. Formula 2 is
##STR00002##
wherein X is O, S, Se, or NH; Y is CH or N; and Ar.sub.1 is a
monocyclic or bicyclic aromatic or heteroaromatic ring system, or a
biphenyl or bipyridyl ring system, or a bridged biphenyl or
bipyridyl ring system, any of which may be further substituted by
one or more halogens (F, Cl, Br, I), NR.sub.1R.sub.2, OR.sub.3,
SO.sub.2NR.sub.4R.sub.5, SR.sub.6, R.sub.7; and wherein R.sub.1,
R.sub.2, R.sub.3, R.sub.4, R, R.sub.6 and R.sub.7, being the same
or different, are each selected from the group consisting of H, a
C.sub.1 to C.sub.6 straight or branched chain or cycloalkyl ring, a
C.sub.1 to C.sub.6 straight or branched chain acyl group, or an
aryl group.
[0019] In a further aspect methods of the invention include using
compositions comprising Formula 2, pharmaceutically acceptable
salts of Formula 2, or combinations thereof. Specifically, the
invention provides methods of inhibiting a botulinum neurotoxin in
a subject by administering to the subject a composition comprising
at least one compound, or pharmaceutically acceptable salt, of
Formula 2. Compositions of the invention may be administered alone
or as part of a therapy to treat botulism, i.e. an infection by C.
botulinum.
[0020] In another aspect of the invention, the methods of the
invention may be used to inhibit or prevent a C. botulinum
infection, in particular a C. botulinum serotype A infection, by
admixing one or more compositions of Formula 2, or a
pharmaceutically acceptable salt thereof, with a substance
suspected of including or being exposed to C. botulinum prior to
such substance being ingested by a subject or such substance
contacting another substance that is expected to be ingested by a
subject.
[0021] The invention also provides kits suitable for use with
methods of the invention. Such kits include at least one
composition of Formula 1, Formula 2, a pharmaceutically acceptable
salt of either Formula 1 or Formula 2, or a combination thereof.
Kits of the invention may also include instructions, a container
for a composition of the invention, and components such as an
adjuvant, diluent, pharmaceutically acceptable carrier and the like
that may be admixed with a composition of the invention.
[0022] "Alkyl" alone or in combination means from 1 to 15,
preferably 1 to 6, carbon atoms. Unless otherwise specified, an
alkyl group is inclusive of a straight chain alkyl, branched alkyl,
or cycloalkyl.
[0023] "Acyl" denotes groups --C(O)R, where R is hydrogen, lower
alkyl, substituted lower alkyl, aryl, substituted aryl and the
like.
[0024] "Aryl" refers to any functional group or substituent derived
from a simple aromatic ring, may it be phenyl, pyridyl, furyl,
thiopheneyl, indolyl, quinolinyl, etc. Simple aryl groups include
phenyl, C.sub.6Hs, which is derived from benzene, the tolyl group,
CH.sub.3C.sub.6H.sub.4, which is derived from toluene
(methylbenzene), and the pyridyl group, C.sub.5H.sub.4N, which is
derived from pyridine. Preferred aryl groups are simple aryl
groups.
[0025] Herein, a "subject" is an animal or human. "Animal" refers
to a fish, bird, or mammal, preferably the animal is a mammal such
as a cat, dog, ungulate (e.g. horse, zebra, donkey, cattle/bison,
rhinoceros, camel, hippopotamus, goat, swine, sheep, giraffe,
okapi, moose, deer, tapir, antelope, or gazelle), rodent (e.g.
mice, rats, and other small, gnawing mammals), bat, bear, primate,
or cetacean.
[0026] Herein, "to inhibit or prevent a C. botulinum infection"
means that one more symptoms associated with a C. botulinum
infection is reduced by at least 10% in a subject as compared to a
subject that receives no therapeutic treatment for a C. botulinum
infection.
[0027] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as is commonly understood by one
of skill in the art to which this invention belongs at the time of
filing. All patents and publications referred to herein are
incorporated by reference herein.
[0028] Other objects, features and advantages of the present
invention will become apparent from the following detailed
description. It should be understood, however, that the detailed
description and the specific examples, while indicating preferred
embodiments of the invention, are given by way of illustration
only, since various changes and modifications within the spirit and
scope of the invention will become apparent to those skilled in the
art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0029] The following drawings form part of the present
specification and are included to further demonstrate certain
aspects of the present invention. The invention may be better
understood by reference to one or more of these drawings in
combination with the detailed description of specific embodiments
presented herein. The application contains at least one drawing
executed in color. Copies of this patent application publication
with color drawing(s) will be provided by the Office upon request
and payment of the necessary fee.
[0030] FIG. 1. Integrated experimental flow-chart to identify
BoNT/A small-molecule inhibitors.
[0031] FIG. 2 shows the efficacy of small-molecules in inhibiting
SNAP-25 cleavage.
[0032] FIG. 2A. The reaction products were analyzed on SDS-PAGE
gels. Lane 1, S25 alone; Lanes 2-7 contained S25+rELC; Lane 3, +NSC
84096; Lane 4, +CB 7967495; Lane 5, +CB 7969312; Lane 6, +NSC
84094; Lane 7, +CB 79698218. FIGS. 2B and 2C. Inhibition of
BoNT/A-mediated SNAP-25 cleavage by small-molecules in cell-based
assay. Efficacy of five small-molecule inhibitors at 15 mM (FIG.
2B) and at 10 mM (FIG. 2C) is shown: Lane 1 (With BoNT/A), Lane 2
(Without BoNT/A), Lanes 3-7 contained BoNT/A with inhibitor; Lane 3
(+NSC 84096), Lane 4 (+CB 7967495), Lane 5 (+CB 7969312), Lane 6
(+NSC 84094), Lane 7 (+CB 7968218). These blots represent three
independent experiments.
[0033] FIG. 3. Effects of BoNT/A small-molecule inhibitors in mouse
phrenic nerve hemidiaphragm assay (MPNHDA). In all assays, BoNT/A
(+) and No Toxin (.DELTA.) controls were run to demonstrate the
difference in twitch tension between BoNT-intoxicated and normal
tissues (n=18 for both groups). The twitch tension time courses are
the averages of triplicate assays. The time courses include only
the effective concentration of inhibitor required for maximum
protection, except for CRATKML which was not effective at the
tested concentration: (.box-solid.) CB 7969312 (500 nM),
(.tangle-solidup.) CB 7967495 (5 .mu.M), (.smallcircle.) NSC 84094
(10 .mu.M), (.diamond-solid.) CB 7968218 (10 .mu.M), (x) NSC 84096
(20 .mu.M), and (.circle-solid.) CRATKML (20 M).
[0034] FIG. 4. Binding mode of NSC 84094 into BoNT/ALC substrate
binding cleft showing the quinolinol group (light green)
interacting with the Zn atom (light blue), while the pyridyl
substituent can form hydrogen bond with Arg363. Atom colors:
nitrogen (blue), oxygen (red), hydrogen (white), enzyme C atoms
(dark green) and inhibitor C atoms (light green).
DETAILED DESCRIPTION
[0035] The invention provides small-molecule inhibitors of C.
botulinum neurotoxin serotype A (BoNT/A), as well as, methods of
using these small molecule inhibitors to inhibit or treat
botulism.
[0036] Eight small-molecule inhibitors of BoNT serotype A were
initially identified by using in silico screening of the NCI
database followed by HPLC protease assays (see Table 1). A
substructure/similarity search was used to identify analogs of the
lead hit NSC 1010 (see Table 2), and focus was placed on five of
its most potent analogs, i.e., NSC 84094, NSC 84096, CB 7967495, CB
7968218 and CB 7969312 (see Table 3). Not only were these five
analogs highly effective against the full-length BoNT/A LC in the
HPLC-based assays, they were also very active against a truncated
form (1-425) of BoNT/A LC. The extent of inhibition and the
IC.sub.50 values of these leads were comparable to or even better
than those of previously reported small-molecule inhibitors (5, 6,
9-12, 15, 29, 32). No small-molecule is known to have been
previously found to be active against both full-length and
truncated forms of BoNT/A LC. Currently, it still remains unclear
what form of light chain exists in the cytosol during the actual
BoNT catalysis of SNARE proteins.
[0037] The crystal structures of the endopeptidase of different
serotypes of BoNT are very similar. The HEXXH (SEQ ID NO: 4) motif
that is characteristic of the catalytic site of Zn-endopeptidase is
conserved. For instance, the active sites of BoNT/A and BoNT/B
endopeptidases differ only in two residues: F162 and F193 in BoNT/A
correspond to N169 and S200 in BoNT/B (32). Thus, it is conceivable
for some BoNT/A inhibitors also to be active against other
serotypes. Here, the five analogs exhibited cross reactivity,
albeit reduced, against BoNT/B LC. Such a finding is not
unprecedented. The two inhibitors described by Tang et al. (47)
were also reported to inhibit BoNT/B LC at concentrations >20
.mu.M. Interestingly, all five compounds (at 240 .mu.M) failed to
inhibit BoNT serotype E light chain. This finding seems to suggest
that they are more selective to serotype A.
[0038] It is also significant that efficacy of these candidate
inhibitors was observed against BoNT/A holotoxin in cellular
assays. Cells treated with all five compounds showed protection
from the deleterious effects BoNT/A had on SNAP-25 at
concentrations lower than the effective levels of previously
reported small-molecule inhibitors (5, 9, 15). Of further
importance is the observation that these five compounds exhibited
little or no cell toxicity, a characteristic that is highly
desirable in the development of a therapeutic drug. Unlike several
BoNT/A small-molecule inhibitors that were reported cytotoxic at
>5 .mu.M (15) or >40 .mu.M (9), four of the compounds (NSC
84096, CB 7969312, NSC 84094, and CB 7967495) were well-tolerated
by the cells at concentrations up to 50 .mu.M, and one (CB 7968218)
exhibited signs of toxicity (aggregation and detachment of N2a
cells from the plate surfaces) only at concentrations above 45
.mu.M.
[0039] The findings in the tissue-based assay revealed that all
five compounds were highly effective in the MPNHDA, significantly
delaying the BoNT/A-induced paralytic half-time by at least
threefold, while the peptide BoNT/A inhibitor Ac-CRATKML-NH.sub.2
(SEQ ID NO: 1) was not protective. Among the five lead inhibitors,
CB 7969312 was the most effective, at 0.5 .mu.M. This striking
observation represents CB 7969312 to be the most potent
small-molecule BoNT/A inhibitor reported to date that exhibited
activity in a tissue-based assay. While the in vivo mouse bioassay
is preferred for evaluating the efficacy of candidate BoNT
inhibitors, during the early phase of drug discovery and
development, the ex vivo MPNHDA has a potential over the in vivo
assay in that it requires only two mice per sample tested, and the
results can be available within hours.
[0040] The effectiveness of these inhibitors in the in vitro and ex
vivo assays was only demonstrated when the compound was premixed
with BoNT/A toxin; pre-loading the inhibitor did not protect
cells/tissues against BoNT intoxication. To date, no one is known
to have been able to provide experimental evidence showing that
inhibitors work in a pre-loading system. The small-molecule
inhibitor that was reported to be active in primary neurons (9) was
demonstrated to show a dose-dependent inhibition of SNAP-25
cleavage in a non-pre-loading system (cells were pretreated with
inhibitor for 45 minutes followed by incubation with BoNT/A in the
continuous presence of inhibitor). Additionally, the inhibitors
reported by Eubanks et al. (15) and Boldt et al. (7) were
characterized in cell culture assays that involved mixing BoNT/A
toxin and varying concentrations of inhibitor.
[0041] The small-molecule inhibitors identified herein have three
aromatic groups, one of which is an 8-quinolinol moiety. Quinolinol
is known to chelate divalent cations (14) and also has
antimicrobial properties (18, 19). Because of potential
indiscriminate metal chelation, the 8-hydroxyquinoline motif has
been tagged as a "not suitable" functional component of BoNT/A LC
inhibitors (1). However, the particular class of quinolinol
identified herein (with the other two ring systems and a secondary
amine, see Tables 2 and 3) displayed specificity for BoNT serotype
A and did not inhibit simply by chelating active-site zinc.
[0042] The structures of the quinolinol derivatives also contain
additional basic moieties, including 2-amino or 3-amino pyridine
(NSC 84094, CB 7967495, CB 7968218, and CB 7969312). The presence
of these structural motifs suggests that these lead inhibitors may
interact with the hydrophobic pocket located in the active site of
the LC (see FIG. 4). Adler et al. (1) reported that the quinolinol
moiety alone in the presence of zinc did not inhibit the
proteolytic activity of BoNT serotypes A and B.
[0043] While the mechanism by which these newly identified
small-molecules inhibit BoNT/A is still being elucidated, molecular
docking provided key insights into the likely binding sites and
mode of inhibition. As shown in FIG. 4, NSC 84094 is docked in the
large hydrophobic pocket of the BoNT/A LC active site, and its
hydroxyquinoline moiety coordinates with zinc, which could explain
the importance of this group in inhibiting BoNT/A LC, and suggests
that the quinolinols inhibit BoNT/A by blocking the active site
zinc. Additionally, the pyridyl ring can form a hydrogen bond with
Arg363, and may contribute to the specificity and potency of the
inhibitor. It should be noted that the crystal structures of the
complexes of known small-molecule and peptide inhibitors with
BoNT/A LC have shown that chelation to zinc is involved in the
binding and inhibition of the light chain in both cases (45, 46). A
small molecule inhibitor reported to have some in vivo efficacy
(15) is a zinc chelator (5). Chelation appears to be a necessary
but not sole condition of known inhibitors. Further studies are
warranted to fully determine the precise mechanism of action of
these compounds.
[0044] In summary, the five small-molecule compounds represent
highly potent, non-toxic BoNT/A inhibitors that were identified
using an integrated screening strategy. These compounds effectively
inhibited the protease activities of both BoNT/A LC (full-length
and truncated), and also significantly neutralized BoNT/A holotoxin
in N2a cells and hemidiaphragm assays. Such protection at the
cellular and tissue levels is particularly important, since
previously reported potent BoNT/A LC inhibitors such as
Ac-CRATKML-NH.sub.2 (SEQ ID NO: 1) were ineffective under these
conditions. Moreover, the effective inhibition by these compounds
of BoNT/A LC, but not BoNT/E LC, as well as their reduced
efficiency of BoNT/B LC, suggest that these small-molecules
preferentially interact with BoNT/A LC.
Pharmaceutical Preparations
[0045] Examples of a pharmaceutically acceptable carrier that may
be used for preparation of the compositions of the present
invention include various organic or inorganic carriers that are
conventionally used as a pharmaceutical material. For example,
excipients, lubricants, binders and disintegrators can be used for
solid preparations; and solvents, solubilizing agents, suspending
agents, isotonic agents, buffer agents, soothing agents, etc., can
be used for liquid preparations. If necessary, conventional
additives such as preservatives, antioxidants, coloring agents,
sweetening agents, adsorbing agents and wetting agents can be also
used in an appropriate amount. Those of skill in the art will be
familiar with the carriers, diluents, adjuvants, etc. that are
recommended for the subject to whom compositions of the invention
are to be administered.
Administration to a Subject
[0046] Similarly, those of skill in the art will recognize that the
preferred dosage to be administered to a subject will depend upon
the species, gender, age, weight, and other health aspects of the
subject. In addition, if the compositions of the invention are
administered as part of a combination therapy for botulism or
infection by a C. botulinum, the effects of the other therapeutic
substances, alone and in combination, must be considered in
determining the proper dosage and time of administration to the
subject.
EXAMPLES
[0047] The following examples are included to demonstrate preferred
embodiments of the invention. It should be appreciated by those of
skill in the art that the techniques disclosed in the examples
which follow represent techniques discovered by the inventors to
function well in the practice of the invention, and thus can be
considered to constitute preferred modes for its practice. However,
those of skill in the art should, in light of the present
disclosure, appreciate that many changes can be made in the
specific embodiments which are disclosed and still obtain a like or
similar result without departing from the spirit and scope of the
invention.
Materials and Methods
[0048] Initial test compounds were obtained from the Drug Synthesis
and Chemistry Branch, Developmental Therapeutics Program, Division
of Cancer Treatment and Diagnosis, National Cancer Institute (NCI;
Bethesda, Md.), Sigma-Aldrich (St. Louis, Mo.) and Chembridge (CB)
Corporation (San Diego, Calif.). Compounds that passed the
preliminary HPLC screening were synthesized and purified by
GLSynthesis, Inc. (Worcester, Mass.). The chemical structure and
purity (>98%) of these analogs were verified and confirmed by
LC-MS and NMR prior to use in subsequent assays. Molecular weights
of the compounds were confirmed by mass spectrometry. All compounds
tested were racemic mixtures.
[0049] The BoNT/A peptide inhibitor (Ac-CRATKML-NH.sub.2) (SEQ ID
NO: 1) was purchased from EMD Chemicals, Inc. (La Jolla, Calif.).
Recombinant full-length BoNT/A and BoNT/B LCs were prepared
according to procedures previously described by Gilsdorf et al.
(20) and Jensen et al. (24), both of which are incorporated by
reference, and were >97% pure based on SDS-PAGE gels. The
recombinant light chain for the type E neurotoxin (rELC; residues
1-423, SEQ ID NO: 8) and truncated type A light chain (tALC,
residues 1-425, SEQ ID NO: 6) were cloned, expressed, and purified.
Briefly, rELC is encoded by the nucelotide sequence provided in SEQ
ID NO: 7; tALC is encoded by the nucelotide sequence provided in
SEQ ID NO: 5. rELC with a C-terminal 6.times.His-tag, and tALC were
cloned and expressed in E. coli (pET24a+/BL21(DE3)). Purification
of rELC was by affinity chromatography, followed by anion exchange
chromatography. Purification of tALC involved a three-step ion
exchange chromatography using Poros HS, Poros HQ, and Source 15S
columns. The purity of rELC and tALC exceeded 90% and 97%,
respectively, as judged by SDS/PAGE. Protein concentration was
measured by BCA using BSA as a standard.
[0050] Botulinum neurotoxin serotype A (Hall strain) was obtained
from Metabiologics (Madison, Wis.). The specific toxicity of the
toxin was 2.4.times.10.sup.8 mouse i.p. LD.sub.50/mg of protein, as
determined by a toxin titration procedure described previously
(25). Synthetic peptides used as substrates for the HPLC assays
were custom synthesized to >98% purity by Quality Controlled
Biochemicals (Hopkinton, Mass.). The Alliance HPLC System (2695 XE
Separation Module and 2996 Photodiode Array Detector) and the
Empower/Millenium software were from Waters (Milford, Mass.). HPLC
columns (Hi-Pore C18, 0.45.times.25 cm) were obtained from Bio-Rad
Laboratories (Hercules, Calif.). Anti-SNAP-25 mouse monoclonal
IgG.sub.1 (SMI-81) was from CRP, Inc. (Berkeley, Calif.) and goat
anti-mouse horseradish-peroxidase-conjugated was from KPL, Inc.
(Gaithersburg, Md.). Cell culture media and reagents were from
Lonza (Walkersville, Md.). ECL Advance Western Blotting Detection
Kit was from GE Healthcare (Piscataway, N.J.). Tyrode's buffer was
purchased from Sigma (St. Louis, Mo.).
Virtual Screening of BoNT/a Inhibitors
[0051] The three-dimensional structure of BoNT/A LC (PDB code:
1E1H) (39) obtained from the Protein Databank was used for virtual
screening since it was the only suiTable 1 vailable crystal
structure at the time the in silico screening was performed. One of
the protomers was removed to vacate the active site. All water
molecules were removed. Hydrogens and all-atom Kollman charges were
added using the BIOPOLYMER module from SYBYL. The three-dimensional
structures of small-molecules for docking were generated using
Concord as implemented in SYBYL. DOCK 4.0 (16) was used for
docking. Zinc parameters were optimized using the same training set
as described by Hu et al. (23). In all cases, the scoring grids
were defined to include the whole active site around the Zn. Ligand
fitting with DOCK was employed using anchor-first docking with
matching receptor sites, and using 25 peripheral seeds, 500
orientations, and uniform sampling. Anchors were first minimized,
followed by layer 2 and the whole ligand. Ten thousand minimization
steps were done for further refinement. All-atom representation and
Gasteiger-Marsili empirical atomic partial charges were used for
the ligands.
HPLC-Based BoNT/a and BoNT/B LC Protease Assays
[0052] Selected compounds from virtual screening were tested in
HPLC-based BoNT/A LC and BoNT/B LC enzymatic assays as described
previously by Gul et al. (21) and Schmidt and Bostian (37), both of
which are incorporated herein by reference. The BoNT/A LC assay
mixture contained 50 mM HEPES (pH 7.3), 0.8 mM substrate containing
residues 187-203 of SNAP-25 (Ac-SNKTRIDEANQRATKML-NH.sub.2) (SEQ ID
NO: 2) (37), test compound dissolved in dimethylsulfoxide (DMSO) at
10.times. the final assay concentration, and 4.5-6.0 .mu.g/mL
(110-140 nM) BoNT/A LC. The LC catalyzes the hydrolysis of SEQ ID
NO: 2 between residues Q11 and R12 corresponding to residues Q11
and R12 corresponding to residues 197 and 198 of SNAP-25.
[0053] The BoNT/B LC reaction mixture contained 50 mM HEPES buffer
(pH 7.3), 0.4 mM substrate corresponding to residues 60-94 of human
VAMP-2 (Ac-LSELDDRADALQAGASQFETSAAKLKRKYWWKNLK-NH.sub.2) (SEQ ID
NO: 3) (44), 1 mM DTT, test compound in DMSO and 1.5-2 .mu.g/mL
(30-40 nM) BoNT/B LC. The LC catalyzes the hydrolysis of SEQ ID NO:
3 between residues Q17 and F18, corresponding to residue 76 and 77
of human VAMP-2. In control assays, the test compound was replaced
by DMSO. The reaction was immediately mixed upon adding the light
chain, and incubated at 37.degree. C. for 5 min. Assays were
stopped by acidification with 90 .mu.l of 0.7% trifluoroacetic acid
(TFA). The amount of uncleaved substrate and products were then
measured after separation by reverse-phase HPLC. Solvent A was 0.1%
TFA and solvent B was 70% acetonitrile/0.1% TFA. For assays with
SEQ ID NO: 2, the flow rate was 1.0 mL/min. at 25.degree. C., with
a gradient profile of 10% B (2.5 min.), linear gradient to 36% B
(21 min.), and 100% B (6 min.). For assays with SEQ ID NO: 3 the
flow rate was 1.0 mL/min. at 25.degree. C., with a gradient profile
of 20% B (2.5 min.), linear gradient to 80% B (21 min.), and 100% B
(6 min.).
HPLC-Based BoNT/A and/B Holotoxin Assay
[0054] The BoNT/A toxin assay was based on the method developed by
Schmidt and Bostian (37) with some modification. Specifically,
bovine serum albumin (BSA) was only used as a component of the
buffer to dilute the toxin, hence its final concentration in the
assay was reduced from 1 mg/ml to 167 .mu.g/ml. Sukonpan et al.
(50) reported that BSA binds to a number of organic compounds and
could mask the identification of potential inhibitors. Briefly, the
assay mixture contained 30 mM HEPES buffer (pH 7.3), 0.5 mM
dithiothreitol, 0.25 mM ZnCl.sub.2, 167 .mu.g/ml of BSA, 0.8-0.9 mM
substrate, 200 .mu.M test compound in DMSO, and 335 nM of BoNT/A
toxin. Immediately upon adding the holotoxin, each reaction mixture
was mixed and incubated at 37.degree. C. for 30 min. the reaction
was stopped by acidification with trifluoroacetic acid (TFA). The
amount of uncleaved substrate and products were then measured after
separation by reverse-phase HPLC.
[0055] The BoNT/B toxin assay is similar to the BLC assay described
above with the following modifications: a) the BLC was replaced by
BoNT/B toxin diluted in 0 mM HEPES, pH 7.2+10 mM DTT+20 .mu.M
ZnCl.sub.2; final B toxin concentration in the assay was 5.5. nM,
and b) the reaction mixture was mixed and incubated at 37.degree.
C. for 30 minutes.
Determination of the IC.sub.50
[0056] The 50% inhibitory concentration (IC.sub.50) values against
BoNT/A LC were calculated from nine concentrations of compound by a
log-probit analysis program using the statistical software GraphPad
Prism 4 (GraphPad Software, La Jolla, Calif.).
SNAP-25 Gel Cleavage Assay by Recombinant Light Chain E (rELC)
[0057] Thirteen M recombinant SNAP-25 (List Biological
Laboratories, Inc., Campbell, Calif.) was incubated with 6 .mu.M
recombinant BoNT/E LC (rELC) and 200 .mu.M compound (dissolved in
DMSO at 10.times. the final assay concentration), and incubated at
37.degree. C. for 30 min. The positive control had rELC and DMSO.
Inhibitors (240 .mu.M) and rELC (6.0 .mu.M) were added to
recombinant SNAP-25 (S25; 12.9 .mu.M) and incubated at 37.degree.
C. for 30 min. Reactions were stopped by adding SDS-PAGE buffer and
heating for 5 min at 70.degree. C. Samples were run on 12% Nu-PAGE
Bis Tris gels (Invitrogen, Carlsbad, Calif.) and stained by Simply
Blue (Invitrogen, Carlsbad, Calif.) (see FIG. 2A).
Carboxypeptidase A (CPA) Assay
[0058] The CPA plate assay was performed according to
manufacturer's (Sigma, St. Louis, Mo.) recommendation. Briefly, the
mixture contained sample reaction buffer, ultrapure water, varying
concentrations of compounds dissolved in DMSO, and CPA. The
positive control had CPA and DMSO, and the negative control
contained CPA+CPA inhibitor from potato tuber. The plate was
incubated for 5 minutes at 25.degree. C. and the reaction was
stopped by the addition of stop solution. The absorption at 350 nm
was read and CPA activity was calculated. Percent inhibition was
determined by comparing the CPA activity produced in the reactions
with CPA alone and reactions containing CPA+test compound. Values
are averages of two independent determinations, each in
triplicate.
Cell Culture Assay
[0059] The cell culture assay was based on the procedures of Yowler
et al. (49) and Boldt et al. (7). both of which are incorporated by
reference herein. Briefly, cells of the murine cholinergic
neuroblastoma cell line Neuro-2a (N2a) (ATCC # CCL-131) were
incubated in Eagle's Minimum Essential Medium (EMEM) supplemented
with 10% fetal bovine serum (FBS), 10 mM HEPES, 1% L-glutamine, 100
U/ml penicillin, and 100 .mu.g/ml of streptomycin, in a 75-cm.sup.2
cell culture flask at 37.degree. C. in an atmosphere of 5% CO.sub.2
and 95% air. Upon reaching 70-80% confluency, the medium was
removed and the cells were washed with Dulbecco's
phosphate-buffered saline (DPBS) without Ca.sup.++ or Mg.sup.+.
Cells were pelleted, diluted to 1.5.times.10.sup.5 cells/ml and
plated in 6-well cell culture plates (2 ml/well). After incubation
for 48 h at 37.degree. C. in an atmosphere of 5% CO.sub.2 and 95%
air, the medium was removed and replaced with serum-free medium,
and the cells were grown for an additional 24 h.
[0060] The inhibitor (0.6-0.9 .mu.l of the initial stock of 16.7 mM
in 100% DMSO) was mixed with 1.5 .mu.l BoNT/A (1 mg/ml) in a total
volume of 2.4 .mu.l and incubated for 30 min at 37.degree. C. The
toxin+DMSO (control) or toxin-inhibitor mixture was added to 1 ml
of EMEM without FBS to bring the final concentration of BoNT/A
toxin to 10 nM. The concentration of BoNT/A was calibrated to
produce .gtoreq.50% cleavage of the substrate SNAP-25 in a 24 h
incubation at 37.degree. C. In all samples, including controls, the
final concentration of DMSO was <0.09%.
[0061] At the end of the incubation, the medium was removed, and
the cells were lysed with CelLytic.TM. M (Sigma, St. Louis, Mo.).
Samples were run on 12% NuPAGE Bis-Tris gels (Invitrogen) and
subjected to western blot analysis (see FIGS. 2B and 2C) using anti
SNAP-25 monoclonal antibody (CRP, Inc.), followed by goat
anti-mouse horseradish-peroxidase-conjugated secondary antibody
(KPL, Inc.). Samples were visualized using ECL Advance Western
Blotting Detection Kit (GE Healthcare). Signals were quantitated
using the UN-SCAN-IT Gel.TM. software (Silk Scientific, Orem,
Utah). Data presented are representative of results from three
independent assays.
Mouse Phrenic Nerve Hemidiaphragm Assay (MPNHDA)
[0062] The MPNHDA was conducted based on the procedures of Sheridan
et al. (42), incorporated herein by reference. Female CD-1 mice
(20-25 g) were euthanized with CO.sub.2 and their diaphragms with
attached phrenic nerves were removed. The diaphragms were then
divided into two hemidiaphragms with each section complete with a
phrenic nerve and myoneural junction. Each hemidiaphragm was
attached to an isometric force transducer (Fohr Medical
Instruments, Seeheim, Germany), and its phrenic nerve was secured
to a stimulating electrode. The nerve-muscle preparations were
immersed in separate 10-ml tissue baths containing Tyrode's buffer
(1.8 mM CaCl.sub.2, 1 mM MgCl.sub.2, 2.7 mM KCl, 137 mM NaCl, 0.4
mM NaH.sub.2PO.sub.4, 12 mM NaHCO.sub.3, and 6 mM glucose), pH
7.2-7.4 (Sigma, St. Louis, Mo.). A mixture of 95% air/5% CO.sub.2
gas was passed through the Tyrode's buffer. The tissue baths were
kept at 37.degree. C.
[0063] Each phrenic nerve was stimulated with single supramaximal
pulses (SD9 Stimulators Grass Instruments, Warwick, R.I.) through a
Powerlab/4sp and Bridge Amp relay (ADInstruments, Inc., Colorado
Springs, Colo.) of 0.3 msec duration at 0.03 Hz. The twitch
tensions were digitally recorded by Chart software (ADInstruments,
Inc., Colorado Springs, Colo.) Maximal twitch tensions were
adjusted to 0.75-1.0 g, and the samples were run for 20-30 min to
reach a sTable 2aseline. The inhibitor (dissolved in DMSO at
2.times. the final assay concentration) was mixed with 60 .mu.M
BoNT/A (Metabiologics, Madison, Wis.) in 5 ml of Tyrode's buffer
and incubated for 15-20 min at 37.degree. C. After baseline
stabilization, the toxin-inhibitor mixture was added to a 10-ml
bath with an additional 5 ml of Tyrode's buffer, bringing the final
concentration of BoNT/A toxin to 30 .mu.M. The concentration of
BoNT/A neurotoxin was previously calibrated to induce a 50% loss of
twitch tension in approximately 60 min. In all samples, including
the controls, the final concentration of DMSO was 0.3%.
[0064] For each experiment, four tissue baths were used. One bath
was the BoNT/A toxin-only control. A second bath was an assay
control without toxin or inhibitor. The third and fourth baths
contained toxin plus two different concentrations of inhibitor.
Adding the toxin or the toxin/inhibitor mixture to the bath
initiated the beginning of data collection, which continued for 5 h
or until muscle twitch tension ceased.
[0065] For all preparations, neurotoxin-induced paralysis was
measured as a 50% loss of twitch tension evoked by nerve
stimulation. Estimates of statistical significance were based on
unpaired, two-tailed t-test, with a P value of <0.05 considered
significant, as previously reported (13, 42, 43). Statistical
analysis was performed using SigmaPlot 10 (Systat Software, San
Jose, Calif.).
[0066] Procedures used to obtain mouse tissues were conducted in
compliance with the Animal Welfare Act and other U.S. federal
statutes and regulations relating to animals and experiments
involving animals, and adhered to principles stated in the Guide
for the Care and Use of Laboratory Animals, National Research
Council, 1996. The facility where this research was conducted is
fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International.
Procedure for the Synthesis of 84094 Analogs
[0067] The general synthesis procedure is described in Fernando et
al. (16a) and Phillips (32a), both of which are incorporated herein
by reference. Briefly, these synthetic targets are accessed via the
Betti reaction, a one step single pot reaction that is a
modification of classic Mannich chemistry. The desired aromatic
amine (1.0 mmol) is dissolved in 3 mL of ethanol in a small flask.
To this, the desired aldehyde (1.0 mmol) is added dropwise. The
solution was allowed to stand for 15 to 20 minutes to promote the
formation of the Mannich base. The desired quinolinol (1.0 mmol) is
then dissolved in a minimal amount of ethanol with gentle heating,
and the resulting solution is added to the reaction flask. The
reaction mixture is then allowed to stand until solid precipitate
forms, or until thin layer chromatography indicates that no further
product is being formed. In the case of limited solubility of the
reagents or nucleophilicity of the amine component, a microwave
reactor is used. Depending upon the reactants used the timeframe
for the precipitation of solid product ranges from a few hours to
several months. Purification of the solid precipitate or the crude
reaction mixture via reverse-phase vacuum liquid chromatography
using gradient elution with MeCN--H.sub.2O mixtures yields the pure
desired product in moderate to high yield.
Example 1: Identification of Small-Molecule Inhibitors of Botulinum
Neurotoxins
[0068] The flow chart shown in FIG. 1 outlines the overall strategy
for the identification of small-molecule inhibitors of BoNT/A.
Focus was placed on serotype A since it is the most prevalent and
well-studied among the various serotypes in human intoxication. In
silico screening was used to identify BoNT/A inhibitors. Selected
compounds were tested for inhibition of the protease activity of
BoNT/A LC. Compounds that passed the HPLC screens were advanced to
in vitro and ex vivo assays.
Virtual Screening of the NCI Database
[0069] The NCI database was chosen for virtual screening on the
basis of the following considerations. First, it constitutes the
largest freely available, public domain chemical structure database
with >250,000 compounds (48). Second, it contains a high number
of unique and structurally diverse compounds. Thus, the NCI
database provides an opportunity to discover lead compounds
(48).
[0070] The compounds from the NCI database were docked into the
active site in one of the protomers of BoNT/A LC (PDB code: 1E1H)
(39) after removing the peptide occupying the active site in the
protomer. The top scoring 500 compounds were evaluated in more
detail; the list was narrowed to 100 structurally-diverse compounds
that interacted well with the active site Zn and demonstrated a
good fit in the BoNT/A LC binding site.
HPLC-BoNT/a LC Protease Assay
[0071] Out of 100 tested, eight compounds were selected that
inhibited BoNT/A, as well as, rALC by more than 60% and 30% at 200
.mu.M and 20 .mu.M, respectively (Table 1). These compounds had
diverse chemical structures with molecular weights ranging from 285
to 622. To determine the actual effectiveness of the compounds
predicted by the virtual screening, an HPLC-based enzymatic assay
was performed in the presence and absence of inhibitor at 20 .mu.M
and 200 .mu.M using full-length recombinant BoNT/A LC (rALC). The
substrate peptide for BoNT/A LC protease activity consisted of
residues 187-203 of SNAP-25, SEQ ID NO: 2, and BoNT/A LC catalyzes
the hydrolysis between residues Q197 and R198 (37). In this study,
focus was placed on the quinolinol lead NSC 1010. Selection of this
compound was based on: (1) NSC 1010 was very potent against rALC;
(2) NSC 1010 failed to inhibit BoNT serotype B light chain (not
shown), suggesting its selectivity for serotype A; (3) there are
quinolinols in clinical trials for Alzheimer's disease and cancer
(22, 33, 34); and (4) quinolinol-based drugs such as linolasept and
vioform (generic name: clioquinol) are available in the market.
TABLE-US-00001 TABLE 1 Structures of selected hits and percent
inhibition against recombinant full-length BoNT/A light chain
(rALC).sup.a. ##STR00003## ##STR00004## ##STR00005## ##STR00006##
##STR00007## ##STR00008## ##STR00009## ##STR00010##
.sup.aStructures were obtained from the NCI Developmental
Therapeutics Program website (See world wide web page at
dtp.nci.nih.gov/index.html/). Compounds were tested in an
HPLC-based assay using recombinant full-length BoNT/A LC (140 nM)
in the presence of 0.8 mM 17-mer SNAP-25 peptide substrate.
Percentages of inhibition at 200 and 20 .mu.M, respectively, are
indicated in parentheses and were determined by the amounts of
peptide substrate cleaved in the presence or absence of inhibitors
under the same conditions.
Screening and Testing Analog Compounds
[0072] To verify chemical identity, NSC 1010 was synthesized, and
its structure and purity confirmed using standard techniques in the
art. Further evaluation of this compound revealed that it was toxic
to neuroblastoma N2a cells in cellular assays at .gtoreq.10 .mu.M.
Similarity searches were performed of Sigma, Chembridge and NCI
databases to look for non-toxic analogs. Fifty-five analogs were
identified and synthesized; structures of the compounds that were
highly potent against the protease activity of BoNT/A (>75%
inhibition) are shown in Table 2. Testing of these analogs in
HPLC-based assays demonstrated five analogs (NSC 84094, NSC 84096,
CB 7967495, CB 7969312, and CB 7968218) to be more potent than the
original hit NSC 1010 and, of equal importance, non-toxic to cells
(see Table 3 below). These five analogs constitute the final
compounds that were subsequently characterized in cell- and
tissue-based assays (see Examples 2 and 3). These compounds are
racemates. Whether one or both of the enantiomers contributed to
the inhibition is unknown since the docking poses for the two
enantiomers of NSC 84096 in the active site of BoNT/A LC were
different but gave comparable scores (not shown). Table 2. Two
dimensional structures of compounds displaying >75% inhibition
(at 200 .mu.M concentration) against BoNT/A light chain.
Identification numbers correspond to those assigned in the NCI and
Chembridge databases.
TABLE-US-00002 TABLE 2 Two dimenstional structures of compounds
displaying >75% inhibition (at 200 .mu.M concentration) against
BoNT/A light chain. Identification numbers correspond to those
assigned in the NCI and Chembridge databases. ##STR00011## NSC
84086 ##STR00012## NSC 84094 ##STR00013## CB 79679495 ##STR00014##
NSC 1010 ##STR00015## NSC 84090 ##STR00016## NSC 84096 ##STR00017##
NSC 84087 ##STR00018## NSC 84093 ##STR00019## NSC 84087
##STR00020## CB 7969312 ##STR00021## CB 7967601 ##STR00022## CB
7967682 ##STR00023## CB 7968687 ##STR00024## CB 7969312
##STR00025## CB 7969927 ##STR00026## CB 7970161 ##STR00027## CB
6372490 ##STR00028## CB 7628245 ##STR00029## CB 7633178
##STR00030## CB 6633504 ##STR00031## CB 6637043 ##STR00032## CB
6381661 ##STR00033## CB 7925368 ##STR00034## CB 6378057
##STR00035## CB 6380823 ##STR00036## CB 6636098 ##STR00037## NSC
84093 ##STR00038## CB 7968218
[0073] To compare the relative inhibitory potencies of the five
analogs, HPLC-based assays were performed using two recombinant
forms of BoNT/A light chain: full-length (rALC) and truncated
(1-425; tALC). Under assay conditions, rALC was at least 4.times.
more active than tALC. The five analogs were very effective against
both forms of BoNT/A LC, demonstrating IC.sub.50 values ranging
from 1.6-4.7 .mu.M and 1.5-5.0 .mu.M for rALC and tALC,
respectively (Table 3).
TABLE-US-00003 TABLE 3 Structural formula and IC.sub.50 values of
selected analogs against recombinant full-length BoNT/A light chain
(rALC) and truncated (1-425) A ligh chain (tALC).sup.a ##STR00039##
##STR00040## ##STR00041## ##STR00042## ##STR00043##
.sup.aStructures were obtained from the NCI Developmental
Therapeutics Program website (see the world wide web page for
dtp.nci.nih.gov/index.html/), and those of CB compounds were from
Chembridge screening compounds and building blocks (see the world
wide web page for hit2lead.com/). All compounds tested were
racemates. The structure and purity of these analogs were confirmed
by LC-MS and NMR. The IC.sub.50 values for rALC and tALC are
indicated in parenthesis, respectively, and were determined from
nine concentrations of each inhibitor using GraphPad Prism 4
(GraphPad Software, La Jolla, CA). rALC (140 nM final
concentration) or tALC (620 nM) was incubated with 0.8 mM 17-mer
SNAP-25 peptide substrate and varying concentrations of inhibitor
(dissolved in DMSO at 10X final concentration) at 37.degree. C. for
5 min in 50 mM HEPES, pH 7.3. Reactions were stopeed by adding 0.7%
TFA and analyzed by reverse-phase HPLC.
[0074] Having established that these five analogs were very potent
against BoNT/A LC, their effects were tested on two related BoNT
endopeptidases: recombinant full-length BoNT/B light chain (rBLC)
and BoNT/E light chain (rELC). The five compounds showed
cross-reactivity against rBLC, with both NSC 84096 and NSC 84094
exhibiting the least inhibition at 6.9% and 8.8%, respectively
(Table 4). However, none of the compounds (at 240 mM) inhibited
rELC in gel cleavage assays (FIG. 2A). Although additional BoNT
light chain serotypes would need to be tested before concluding
that these five compounds are more selective for BoNT/A, this
possibility deserves consideration.
TABLE-US-00004 TABLE 4 Percent inhibition of selected
small-molecules against recombinant BoNT/A light chain (rALC) and
BoNT/B light chain (rBLC) .sup.a % Inhibition Against Compound rALC
rBLC BoNT/A BoNT/B NSC 84096 91.9 .+-. 1.7 6.9 .+-. 2.0 77.8 .+-.
2.0 55.0 .+-. 0.1 NSC 84094 97.4 .+-. 2.2 8.8 .+-. 0.8 85.1 .+-.
0.4 77.1 .+-. 0.0 CB 7967495 92.7 .+-. 1.5 30.2 .+-. 2.4 90.6 .+-.
2.2 86.8 .+-. 0.0 CB 7968218 92.8 .+-. 0.8 16.8 .+-. 2.2 95.6 .+-.
2.1 90.2 .+-. 0.0 CB 7969312 96.2 .+-. 1.2 31.2 .+-. 3.0 71.0 .+-.
0.7 85.0 .+-. 0.0 .sup.a HPLC-based protease assays were conducted
at 37.degree. C. using various inhibitors at 20 .mu.M final
concentration. rALC assays contained 50 mM HEPES (pH 7.3), 0.8 mM
SNAP-25 peptide substrate, test compound in DMSO, and rALC (110-140
nM). The assay for rBLC contained 50 mM HEPES (pH 7.3), 1 mM DTT,
0.4 mM 35-mer VAMP peptide substrate, test compound in DMSO, and
rBLC (30-40 nM). Inhibitors were diluted into the reaction mixture
containing the substrate, followed by the addition of LC (i.e.,
inhibitor and LC were not pre-incubated). Reactions were stopped by
acidification by TFA, and analyzed by reverse-phase HPLC. Data
represent mean .+-. SD from 2 independent assays.
[0075] Further experimental studies revealed that all five
compounds (at concentrations up 20 .mu.M) showed no inhibitory
effect on the zinc protease carboxypeptidase (CPA), while the
control inhibitor from potato tuber exhibited 100% inhibition at
concentrations equal to or greater than 0.187 .mu.M (not shown).
This finding precludes the possibility that the inhibition of
BoNT/A endopeptidase by these analogs was due to nonspecific
chelation.
[0076] Further synthesis and testing of novel analogs of NSC 1010
provided new chemical entities with comparable or improved potency
(Table 5).
TABLE-US-00005 TABLE 5 Previously unreported analogs with potent
activity against BoNT/A % Inhibition against BoNT/A IC.sub.50
Compound Chemical Structure (5 .mu.M) (.mu.M) 5116-047A
##STR00044## 83.0 1.4 5116-048A ##STR00045## 87.0 0.8 5116-050A
##STR00046## 86.7 1.2 5116-051A ##STR00047## 91.0 <1.0 5116-052A
##STR00048## 97.5 <1.0 4874-051A ##STR00049## 94.0 2.2
Example 2: Inhibition in Cell-Based Assay
[0077] To this point, it has been demonstrated that five compounds
inhibit the enzymatic activity of BoNT/A in vitro. To examine the
likelihood that these compounds might be useful antibotulinum
therapeutics, studies were performed in other systems. One of these
used murine neuroblastoma N2a cells to evaluate the ability of
these compounds to protect BoNT/A-mediated cleavage of
intracellular SNAP-25. BoNT/A binds to N2a cells and the
translocated LC cleaves SNAP-25 in these cells. The extent of
cleavage of SNAP-25 in N2a cells by BoNT/A was determined by
western blot analysis using monoclonal antibodies against SNAP-25.
As shown in FIG. 2B, all five lead analogs at 15 .mu.M, exhibited
complete protection of BoNT/A-mediated SNAP-25. At 10 .mu.M, three
of these compounds (CB 7967495, NSC 84094, CB 7969312) showed
near-to-complete inhibition of SNAP-25 cleavage while the other two
(NSC 84096 and CB 7968218) afforded 66% and 68% protection,
respectively (FIG. 2C).
Example 3: Activity in Mouse Phrenic Nerve Hemidiaphragm Assay
[0078] Encouraged by these findings, the efficacy of these analogs
was examined at the tissue level using mouse phrenic nerve
hemidiaphragm preparations whose intact neuromuscular junction
permits the monitoring of the effectiveness of an inhibitor by
recording muscle twitch tension. In the ex-vivo mouse phrenic nerve
hemidiaphragm assay (MPNHDA), the time to onset of neuromuscular
block is a concentration-sensitive event, with blockade occurring
earlier with higher toxin concentrations (13, 40, 41). Changes in
the onset of muscle paralysis with a fixed concentration of toxin
are used to indicate the activity of candidate BoNT
therapeutics.
[0079] Results from MPNHDA experiments demonstrated that applying
effective concentrations of compounds significantly delayed
(P<0.01) the onset of toxin-induced paralysis (Table 6). While
neuromuscular preparations exposed to BoNT/A alone (control)
produced an average paralytic time of 65.7.+-.7.80 min, those that
were exposed to inhibitors at effective concentrations ranged from
216.3-281.0 min. The effective concentrations that caused a delay
in time to 50% loss of twitch tension for the five inhibitors
ranged from 0.5 .mu.M-20 .mu.M. Moreover, the muscle twitch-tension
time courses of the five inhibitors at their effective
concentrations during the entire assay period (300 min) were
comparable to the No Toxin-control group (FIG. 3). By comparison,
the peptide BoNT/A inhibitor Ac-CRATKML-NH.sub.2 (SEQ ID NO: 1)
(K.sub.i=1.9 .mu.M) (38) did not cause a delay in paralytic time at
20 .mu.M, and showed muscle twitch-tension time courses that were
similar to that of BoNT/A alone (control) (FIG. 3). This is the
first report of BoNT/A small-molecule inhibitors that showed
activity in an ex vivo assay.
TABLE-US-00006 TABLE 6 Effect of small-molecule inhibitors in
protecting BoNT/A-induced neuromuscular block in mouse phrenic
nerve hemidiaphragm assays. Average Time Concentration to 50% Loss
of Inhibitor (.mu.M) Twitch Tension (min).sup.a Without BoNT/A --
>300.00 With BoNT/A -- 65.70 .+-. 7.80.sup. BoNT/A + NSC 84096
20.0 216.3 .+-. 20.2.sup.b 0.10 59.7 .+-. 4.9.sup.d BoNT/A + NSC#
84094 10.0 266.3 .+-. 19.6.sup.b 0.25 72.0 .+-. 5.5.sup.c BoNT/A +
CB 7967495 5.00 216.3 .+-. 25.2.sup.b 1.00 58.7 .+-. 7.5.sup.c
BoNT/A + CB 7968218 10.0 281.0 .+-. 19.0.sup.b 0.10 66.3 .+-.
10.6.sup.c BoNT/A + CB 7969312 0.50 271.0 .+-. 29.0.sup.b 0.10 91.7
.+-. 19.6.sup.c BoNT/A + SEQ ID NO: 1 20.0 52.70 .+-. 9.30.sup.c
5.00 65.0 .+-. 11.5.sup.c .sup.aSpecified concentrations of
small-molecule inhibitors and BoNT/A were added to hemidiaphragm
preparations, and isometric contractions of the
electrically-stimulated muscles were recorded and analyzed. The
time required to 50% of loss of twitch tension (paralytic
half-time) was determined. Controls (with and without BoNT/A) used
the same amount of DMSO (0.3% final concentration) as those with
inhibitors. Data are means .+-. SE (n = 3 for small-molecules and
Ac-CRATKML-NH.sub.2 (SEQ ID NO: 1); n = 18 for With BoNT/A and
without BoNT/A control groups). .sup.bP < 0.01, highly
significant; .sup.cP > 0.05, not significant from those recorded
with BoNT/A control. Statistical analysis was performed using
SigmaPlot 10 (Systat Software, San Jose, CA). .sup.dP > 0.05,
not significant from those recorded with BoNT/A alone. Statistical
analhysis was performed using SigmaPlot 10.
[0080] All of the compositions and methods disclosed and claimed
herein can be made and executed without undue experimentation in
light of the present disclosure. While the compositions and methods
of this invention have been described in terms of preferred
embodiments, it will be apparent to those of skill in the art that
variations may be applied to the compositions and methods and in
the steps or in the sequence of steps of the method described
herein without departing from the concept, spirit and scope of the
invention. More specifically, it will be apparent that certain
agents which are both chemically and physiologically related may be
substituted for the agents described herein while the same or
similar results would be achieved. All such similar substitutes and
modifications apparent to those skilled in the art are deemed to be
within the spirit, scope and concept of the invention as defined by
the following claims.
REFERENCES
[0081] The following references, to the extent that they provide
exemplary procedural or other details supplementary to those set
forth herein, are specifically incorporated herein by reference.
[0082] 1. Adler, M., R. E. Dinterman, and R. W. Wannemacher. 1997.
Protection by the heavy metal chelator N,N,N',N'-tetrakis
(2-pyridylmethyl) ethylenediamine (TPEN) against the lethal action
of botulinum neurotoxin A and B. Toxicon 35: 1089-1100. [0083] 2.
Associated Press. Jul. 24, 2007, posting date. Castleberry expands
food recall over link to botulism outbreak. Available on the world
wide web at foxnews.com/story/0,2933,290507,00.html. [0084] 3.
Black, J. D., and J. O. Dolly. 1986. Interaction of 1251-labeled
botulinum neurotoxins with nerve terminals. I. Ultrastructural
autoradiographic localization and quantitation of distinct membrane
acceptors for types A and B on motor nerves. J. Cell Biol. 103(2):
521-534. [0085] 4. Black, J. D., and J. O. Dolly. 1986. Interaction
of 1251-labeled botulinum neurotoxins with nerve terminals. II.
Autoradiographic evidence for its uptake into motor nerves by
acceptor-mediated endocytosis. J. Cell Biol. 103(2): 535-544.
[0086] 5. Boldt, G. E., J. P. Kennedy, and K. D. Janda. 2006.
Identification of a potent botulinum neurotoxin A protease
inhibitor using in situ lead identification chemistry. Org. Lett.
8: 1729. [0087] 6. Boldt, G. E., J. P. Kennedy, M. S. Hixon, L. A.
McAllister, J. T. Barbieri, S. Tzipori, and K. D. Janda. 2006.
Synthesis, characterization and development of a high-throughput
methodology for the discovery of botulinum neurotoxin a inhibitors.
J. Comb. Chem. 8(4): 513-521. [0088] 7. Boldt, G. E., L. M.
Eubanks, and K. D. Janda. 2006. Identification of a botulinum
neurotoxin A protease inhibitor displaying efficacy in a cellular
model. Chem. Commun. (Camb.) 29: 3063-3065. [0089] 8. Breidenbach,
M. A., and A. T. Brunger. 2004. Substrate recognition strategy for
botulinum neurotoxin serotype A. Nature 432(7019): 925-929. [0090]
9. Burnett, J. C., G. Ruthel, C. M. Stegmann, R. G. Panchal, T. L.
Nguyen, A. R. Hermone, R. G. Stafford, D. G. Lane, T. A. Kenny, C.
F. McGrath, P. Wipf, A. M. Stahl, J. J. Schmidt, R. Gussio, A. T.
Brunger, and S. Bavari. 2007. Inhibition of metalloprotease
botulinum serotype A from a pseudo-peptide binding mode to a
small-molecule that is active in primary neurons. J. Biol. Chem.
282: 5004-5014. [0091] 10. Burnett, J. C., J. J. Schmidt, C. F.
McGrath, T. L. Nguyen, A. R. Hermone, J. L. Vennerstrom, K.
Kodukula, D. W. Zaharevitz, R. Gussio, and S. Bavari. 2005.
Conformational sampling of the botulinum neurotoxin serotype A
light chain: implications for inhibitor binding. Bioorg. Med. Chem.
13: 333-341. [0092] 11. Burnett, J. C., J. J. Schmidt, R. G.
Stafford, R. G. Panchal, T. L. Nguyen, J. L. Vennerstrom. C. F.
McGrath, D. J. Lane, E. A. Sausville, D. W. Zaharevitz, R. Gussio,
and S. Bavari. 2003. Novel small-molecule inhibitors of botulinum
neurotoxin A metalloprotease activity. Biochem. Biophys. Res.
Commun. 310: 84-93. [0093] 12. CapkovA, K., Y. Yoneda, T. J.
Dickerson, and K. D. Janda. 2007. Synthesis and structure-activity
relationships of second-generation hydroxamate botulinum neurotoxin
A protease inhibitors. Bioorg. Med. Chem. Lett. 17(23): 6463-6466.
[0094] 13. Deshpande, S. S., R. E. Sheridan, and M. Adler. 1995. A
study of Zn-dependent metalloendopeptidase inhibitors as
pharmacological antagonists in botulinum neurotoxin poisoning.
Toxicon 33: 551-557. [0095] 14. Deshpande, S. S., R. E. Sheridan,
and M. Adler. 1997. Efficacy of certain quinolines as
pharmacological antagonists in botulinum neurotoxin poisoning.
Toxicon 35: 433-445. [0096] 15. Eubanks, L. M., M. S. Hickson, W.
Jin, S. Hong, C. M. Clancy, W. H. Tepp, M. R. Baldwin, C. J.
Malizio, M. C. Goodnough, J. T. Barbieri, E. A. Johnson., D. L,
Boger. T. J. Dickerson, and K. D. Janda. 2007. An in vitro and in
vivo disconnect uncovered through high-throughput identification of
botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. USA 104:
2602-2607. [0097] 16. Ewing, T. J., S. Makino, A. G. Skillman, and
I. D. Kuntz. 2001. DOCK 4.0: search strategies for automated
molecular docking of flexible molecule databases. J. Comput. Aided
Mol. Des. 15: 411-428. [0098] 16a. Fernando, Q., R. Keown, and J.
P. Phillips. 1953. The reaction of aldehydes and aromatic amines
with 8-quinolinol. J. Am. Chem. Soc. 75: 4306-4307. [0099] 17.
Foran, P. G., B. Davletov, and F. A. Meunier. 2003. Getting muscles
moving again after botulinum toxin: novel therapeutic challenges.
Trends Mol. Med. 9: 291-299. [0100] 18. Gershon, H., and R.
Pamegiani. 1962. Antimicrobial activity of 8-quinolinol, its salts
with salicylic acid and 3-hydroxy-2-naphthoic acid, and the
respective copper (II) chelates in liquid culture. Appl. Microbiol.
10: 62-65. [0101] 19. Gershon, H., and R. Pamegiani. 1962.
Antimicrobial activity of 8-quinolinols, salicylic acids,
hydroxynaphthoic acids, and salts of selected quinolinols with
selected hydroxy-acids. Appl. Microbiol. 10: 556-560. [0102] 20.
Gilsdorf, J., N. Gul, and L. A. Smith. 2006. Expression,
purification, and characterization of Clostridium botulinum type B
light chain. Protein Expr. Purif. 46(2): 256-267. [0103] 21. Gul,
N., S. A. Ahmed, and L. A. Smith. 2004. Inhibition of the protease
activity of the LC of type A botulinum neurotoxin by aqueous
extract from stinging nettle (Urtica dioica) leaf. Basic Clin.
Pharmacol. Toxicol. 95: 215-219. [0104] 22. Helmuth, L. 2000.
Neuroscience: an antibiotic to treat Alzheimer's? Science 290:
1273-1274. [0105] 23. Hu, X., S. Balaz, and W. H. Shelver. 2004. A
practical approach to docking of zinc metalloproteinase inhibitors.
J. Mol. Graph. Model. 22: 293-307. [0106] 24. Jensen, M. J., T. J.
Smith, S. A. Ahmed, and L. A. Smith. 2003. Expression,
purification, and efficacy of the type A botulinum neurotoxin
catalytic domain fused to two translocation domain variants.
Toxicon 4: 691-701. [0107] 25. Kalb, S. R., T. J. Smith, H. Moura,
K. Hill, J. Lou, I. N. Geren, C. Garcia-Rodriguez, J. D. Marks, L.
A. Smith, J. L Pirkle, and J. R. Barr. 2008 The use of Endopep-MS
to detect multiple subtypes of botulinum neurotoxins A, B, E, and
F. Int J Mass Spectrom 278: 101-108. [0108] 26. Kongsaengdao, S.,
K. Samintarapanya, S. Rusmeechan, A. Wongsa, C. Pothirat, C.
Permpikul, S. Pongpakdee, W. Puavilai, P. Kateruttanakul, U.
Phengtham, K. Panjapompon. J. Janma, K. Piyavechviratana, P.
Sithinamsuwan, A. Deesomchok. S. Tongyoo, W. Vilaichone, K.
Boonyapisit, S. Mayotarn, B. Piya-Isragul, A. Rattanaphon, P.
Intalapaporn, P. Dusitanond, P. Harnsomburana, W. Laowittawas, P.
Chairangsaris, J. Suwantamee, W. Wongmek, R. Ratanarat, A.
Poompichate, H. Panyadilok, N. Sutcharitchan, A. Chuesuwan, P.
Oranrigsupau, C. Sutthapas, S. Tanprawate, J. Orsuwansiri, N.
Phattana; Thai Botulism Study Group. 2006. An outbreak of botulism
in Thailand: clinical manifestations and management of severe
respiratory failure. Clin. Infect. Dis. 43: 1247-1256. [0109] 27.
Lacy, D. B., W. Tepp, A. C. Cohen, B. R. DasGupta, and R. C.
Stevens. 1998. Crystal structure of botulinum neurotoxin type A and
implications for toxicity. Nat. Struct. Biol. 5: 898-902. [0110]
28. McClatchy Newspapers. Jul. 24, 2007, posting date. Botulism
cases spur huge food recall. Available on the world wide web at
omaha.com/index.php?u_page.sup.=1100&u_sid=10086080#list.
[0111] 29. Moe, S. T., A. B. Thompson, G. M. Smith, R. A.
Fredenburg, R. L. Stein, and A. R. Jacobson. 2009. Botulinum
neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide
analogs. Bioorg Med Chem. 17(8): 3072-3079. [0112] 30. Montal, M.
S., R. Blewitt, J. M. Tomich, and M. Montal. 1992. Identification
of an ion channel-forming motif in the primary structure of tetanus
and botulinum neurotoxins. FEBS Lett. 313(1): 12-18. [0113] 31.
Montecucco, C., and G. Schiavo. 1995. Structure and function of
tetanus and botulinum neurotoxins. Quart. Rev. Biophys. 28:
423-472. [0114] 32. Park, J. G., P. C. Sill, E. F. Makiyi, A. T.
Garcia-Sosa, C. B. Millard, J. J. Schmidt, and Y. P. Pang. 2006.
Serotype-selective, small-molecule inhibitors of the zinc
endopeptidase of botulinum neurotoxin serotype A. Bioorg. Med.
Chem. 14: 395-408. [0115] 32a. Phillips, J P. 1956. The reactions
of 8-quinolinol. Chem. Rev. 56: 271-297. [0116] 33. PRNewswire.
Apr. 17, 2007, posting date. Alzheimer's drug shows promise in
fighting cancer. Available on the world wide web at
drugs.com/clinical_trials/alzheimer-s-shows-promise-fighting-cancer-628.h-
tml?printable=1. [0117] 34. Ritchie, C. W., A. I. Bush, A.
Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R.
Cherny, Q. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis,
M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R. E. Tanzi, C. L.
Masters. 2003. Metal-protein attenuation with iodochlorhydroxyquin
(Clioquinol) targeting A.beta. amyloid deposition and toxicity in
Alzheimer Disease, a pilot phase 2 clinical trial. Arch. Neurol.
60: 1685-1691. [0118] 35. Schiavo, G., and M. Montecucco. 1997.
Clostridial neurotoxins, p. 169-186. In K. Aktories (ed.),
Bacterial Toxins: Tools in Cell Biology and Pharmacology, Chapman
and Hall, Weinheim, Germany. [0119] 36. Schiavo, G., O. Rossetto,
and C. Montecucco. 1994. Clostridial neurotoxins as tools to
investigate the molecular events of neurotransmitter release. Sem.
Cell Biol. 5: 221-229. [0120] 37. Schmidt, J. J., and K. A.
Bostian. 1997. Endoproteinase activity of type A botulinum
neurotoxin: substrate requirements and activation by serum albumin.
J. Protein Chem. 16: 19-26. [0121] 38. Schmidt, J. J., R. G.
Stafford, and K. A. Bostian. 1998. Type A botulinum neurotoxin
proteolytic activity: development of competitive inhibitors and
implications for substrate specificity at the S1' binding subsite.
FEBS Lett. 435: 61-64. [0122] 39. Segelke, B., M. Knapp, S.
Kadkhodayan, R. Balhorn, and B. Rupp. 2004. Crystal structure of
Clostridium botulinum neurotoxin protease in a product-bound state:
evidence for noncanonical zinc protease activity. Proc. Natl. Acad.
Sci. USA 101: 6888-6893. [0123] 40. Simpson, L. L., and B. R.
Dasgupta. 1983. Botulinum neurotoxin type E: studies on mechanism
of action and on structure-activity relationships. J. Pharmacol.
Exp. Ther. 224: 135-140. [0124] 41. Simpson, L. L., J. A. Coffield,
and N. Bakry. 1993. Chelation of zinc antagonizes the neuromuscular
blocking properties of the seven serotypes of botulinum neurotoxin
as well as tetanus toxin. J. Pharmacol. Exp. Ther. 267: 720-727.
[0125] 42. Sheridan, R. E., S. S. Deshpande, J. D. Nicholson, and
M. Adler. 1997. Structural features of aminoquinolines necessary
for antagonist activity against botulinum neurotoxin. Toxicon 35:
1439-1451. [0126] 43. Sheridan, R. E., S. S. Deshpande, and T.
Smith. 1999. Comparison of in vivo and in vitro mouse bioassays for
botulinum toxin antagonists. J. Appl. Toxicol. 19: S29-S33. [0127]
44. Shone, C. C., and A. K. Roberts. 1994. Peptide substrate
specificity and properties of the zinc-endopeptidase activity of
botulinum type B neurotoxin. Eur. J. Biochem. 225: 263-270. [0128]
45. Silvaggi, N. R., D. Wilson, S. Tzipori, and K. N. Allen. 2008.
Catalytic features of the botulinum neurotoxin A light chain
revealed by high resolution structure of an inhibitory peptide
complex. Biochemistry 47: 5736-5745. [0129] 46. Silvaggi, N. R., G.
E. Boldt, M. S. Hixon, J. P Kennedy, S. Tzipori, K. D. Janda, and
K. N. Allen. 2007. Structures of Clostridium botulinum neurotoxin
serotype A light chain complexed with small-molecule inhibitors
highlight active-site flexibility. Chemistry and Biology 14:
533-542. [0130] 47. Tang, J., J. G. Park, C. B. Millard, J. J.
Schmidt, and Y. P. Pang. 2007. Computer-aided lead optimization:
improved small-molecule inhibitor of the zinc endopeptidase of
botulinum neurotoxin serotype A. PLoS ONE. 2(8):e761.
doi:10.1371/journal.pone.0000761. [0131] 48. Voigt, J. H., B.
Bienfait, S. Wang, and M. C. Nicklaus. 2001. Comparison of the NCI
open database with seven large chemical structural databases. J.
Chem. Inf. Comput. Sci. 41: 702-712. [0132] 49. Yowler, B. C., R.
D. Kensinger, and C. L. Schengrund. 2002. Botulinum neurotoxin A
activity is dependent upon the presence of specific gangliosides in
neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem. 277:
32815-32819. [0133] 50. Sukonpan, C. et al. 2004. Synthesis of
substrates and inhibitors of botulinum neurotoxin type A
metalloprotease. J. Pept. Res. 63: 181-93.
Sequence CWU 1
1
817PRTArtificial Sequencepeptide inhibitor of Clostridium botulism
neurotoxin serotype A commercially available from EMD Chemicals
Inc.MISC_FEATUREThe n-terminal contains a variable acetyl
sequenceMISC_FEATUREThe c-terminal contains an amino group 1Cys Arg
Ala Thr Lys Met Leu1 5217PRTHomo sapiensMISC_FEATUREThe n-terminal
contains a variable acetyl sequenceMISC_FEATUREThe c-terminal
contains an amino group 2Ser Asn Lys Thr Arg Ile Asp Glu Ala Asn
Gln Arg Ala Thr Lys Met1 5 10 15Leu335PRTHomo
sapiensMISC_FEATUREThe n-terminal contains a variable acetyl
sequenceMISC_FEATUREThe c-terminal contains an amino group 3Leu Ser
Glu Leu Asp Asp Arg Ala Asp Ala Leu Gln Ala Gly Ala Ser1 5 10 15Gln
Phe Glu Thr Ser Ala Ala Lys Leu Lys Arg Lys Tyr Trp Trp Lys 20 25
30Asn Leu Lys 3545PRTClostridium botulinummisc_feature(3)..(4)Xaa
can be any naturally occurring amino acid 4His Glu Xaa Xaa His1
551275DNAClostridium botulinummisc_featureThe n-terminal contains a
variable acetyl sequencemisc_featureThe c-terminal contains an
amino group 5atgcagttcg ttaacaaaca gttcaactac aaagacccgg ttaacggtgt
tgacatcgct 60tacatcaaaa tcccgaacgt tggtcagatg cagccggtta aagcattcaa
aatccacaac 120aaaatctggg ttatcccgga acgtgacact ttcactaacc
cggaagaagg tgacctgaac 180ccgccgccgg aagctaaaca ggttccggtt
tcttactacg actctactta cctgtctact 240gacaacgaaa aggacaacta
cctgaaaggt gttactaaac tgtttgaacg tatctactct 300actgacctgg
gtcgcatgct gctcacttct atcgttcgtg gtatcccgtt ctggggtggt
360tctactatcg acactgaact gaaagttatc gacactaact gcatcaacgt
tatccagccg 420gacggttctt accgttctga agaactgaac ctggttatca
tcggtccgtc tgctgacatc 480atccagtttg aatgcaaatc tttcggtcac
gaagttctga acctgactcg taacggttac 540ggttctactc agtacatccg
tttctctccg gacttcactt tcggtttcga agaatctctg 600gaagttgaca
ctaacccgct gctgggtgct ggtaaattcg ctactgaccc ggctgttact
660ctggctcacg aactgatcca cgctggtcac cgtctgtacg gtatcgctat
caacccgaac 720cgtgttttca aagttaacac taacgcttac tacgaaatgt
ctggtctgga agtttctttt 780gaagaactgc gtactttcgg tggtcacgac
gctaaattca tcgactctct gcaggaaaac 840gagttccgtc tgtactacta
caacaaattc aaagacatcg cttctactct gaacaaagct 900aaatctatcg
ttggtaccac tgcttctctg cagtacatga agaacgtttt caaagaaaag
960tacctgctgt ctgaagacac ttctggtaaa ttctctgttg acaaactgaa
attcgacaaa 1020ctgtacaaaa tgctgactga aatctacact gaagacaact
tcgttaaatt cttcaaagtt 1080ctgaaccgta aaacttacct gaacttcgac
aaagctgttt tcaaaatcaa catcgttccg 1140aaagttaact acactatcta
cgacggtttc aacctgcgta acactaacct ggctgctaac 1200ttcaacggtc
agaacactga aatcaacaac atgaacttca ctaaactgaa gaacttcact
1260ggtctgtttg agttc 12756425PRTClostridium botulinum 6Met Gln Phe
Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly1 5 10 15Val Asp
Ile Ala Tyr Ile Lys Ile Pro Asn Val Gly Gln Met Gln Pro 20 25 30Val
Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg 35 40
45Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu
50 55 60Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser
Thr65 70 75 80Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys
Leu Phe Glu 85 90 95Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu
Thr Ser Ile Val 100 105 110Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr
Ile Asp Thr Glu Leu Lys 115 120 125Val Ile Asp Thr Asn Cys Ile Asn
Val Ile Gln Pro Asp Gly Ser Tyr 130 135 140Arg Ser Glu Glu Leu Asn
Leu Val Ile Ile Gly Pro Ser Ala Asp Ile145 150 155 160Ile Gln Phe
Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr 165 170 175Arg
Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe 180 185
190Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
195 200 205Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
His Glu 210 215 220Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala
Ile Asn Pro Asn225 230 235 240Arg Val Phe Lys Val Asn Thr Asn Ala
Tyr Tyr Glu Met Ser Gly Leu 245 250 255Glu Val Ser Phe Glu Glu Leu
Arg Thr Phe Gly Gly His Asp Ala Lys 260 265 270Phe Ile Asp Ser Leu
Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn 275 280 285Lys Phe Lys
Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val 290 295 300Gly
Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys305 310
315 320Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys
Leu 325 330 335Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr
Thr Glu Asp 340 345 350Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg
Lys Thr Tyr Leu Asn 355 360 365Phe Asp Lys Ala Val Phe Lys Ile Asn
Ile Val Pro Lys Val Asn Tyr 370 375 380Thr Ile Tyr Asp Gly Phe Asn
Leu Arg Asn Thr Asn Leu Ala Ala Asn385 390 395 400Phe Asn Gly Gln
Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu 405 410 415Lys Asn
Phe Thr Gly Leu Phe Glu Phe 420 42571293DNAClostridium botulinum
7atgccgaaaa tcaactcgtt caactacaac gacccggtga atgaccgcac aatcctgtac
60attaagccgg gcggttgcca ggagttctac aagagcttta acattatgaa gaacatctgg
120atcatccctg aacgcaatgt gatcgggaca acgccacaag atttccaccc
tccgacttcg 180ctcaaaaacg gggactcctc ctactacgac ccaaattact
tgcaaagcga tgaggagaaa 240gatcggttcc tgaagattgt gacaaagatc
ttcaaccgta ttaacaacaa tctctcgggg 300ggcatcctcc tggaggaatt
atccaaggcg aacccttacc tgggcaacga caacactcca 360gacaaccagt
tccacattgg cgacgcctcc gcggtggaga tcaagttctc gaatggcagt
420caggacatcc ttctccctaa tgtcattatt atgggcgccg agccggacct
ttttgaaacc 480aattccagca acatctcgct gcgcaacaac tacatgccga
gcaatcacgg ctttgggtcg 540atcgcgatcg tgactttctc gccggagtac
tcctttcgct tcaacgacaa ctccatgaac 600gagttcattc aggacccggc
gctcaccctc atgcacgagc tgatccactc gttacatggc 660ttgtacggcg
cgaaggggat cacgaccaag tataccatta cgcagaaaca gaacccactt
720atcacgaaca tccgtgggac gaacatcgag gagttcctca cgttcggggg
gaccgacctg 780aacattatca ccagcgccca gtccaacgac atttacacga
acctgctggc agattacaaa 840aaaattgcct ccaagctctc caaggtccag
gtatcgaacc cgttgctcaa tccttacaag 900gacgtcttcg aggctaagta
tgggctggat aaggatgcct caggaatcta ctctgtgaac 960atcaacaaat
tcaacgacat cttcaagaag ctgtacagct tcaccgagtt tgacctcgcc
1020accaagttcc aggtcaaatg tcggcaaacg tacattggcc agtataaata
ttttaagctg 1080tcgaatcttc tcaacgactc tatctataac atctccgagg
ggtacaatat taacaactta 1140aaagtcaact tccgagggca gaacgcaaat
ctcaacccac ggattattac tcctattaca 1200ggccgcgggc tcgtcaagaa
gatcatccga ttttgcaaaa acattgtcag cgttaaaggc 1260atccgtaagc
tcgagcacca ccaccaccac cac 12938431PRTClostridium botulinum 8Met Pro
Lys Ile Asn Ser Phe Asn Tyr Asn Asp Pro Val Asn Asp Arg1 5 10 15Thr
Ile Leu Tyr Ile Lys Pro Gly Gly Cys Gln Glu Phe Tyr Lys Ser 20 25
30Phe Asn Ile Met Lys Asn Ile Trp Ile Ile Pro Glu Arg Asn Val Ile
35 40 45Gly Thr Thr Pro Gln Asp Phe His Pro Pro Thr Ser Leu Lys Asn
Gly 50 55 60Asp Ser Ser Tyr Tyr Asp Pro Asn Tyr Leu Gln Ser Asp Glu
Glu Lys65 70 75 80Asp Arg Phe Leu Lys Ile Val Thr Lys Ile Phe Asn
Arg Ile Asn Asn 85 90 95Asn Leu Ser Gly Gly Ile Leu Leu Glu Glu Leu
Ser Lys Ala Asn Pro 100 105 110Tyr Leu Gly Asn Asp Asn Thr Pro Asp
Asn Gln Phe His Ile Gly Asp 115 120 125Ala Ser Ala Val Glu Ile Lys
Phe Ser Asn Gly Ser Gln Asp Ile Leu 130 135 140Leu Pro Asn Val Ile
Ile Met Gly Ala Glu Pro Asp Leu Phe Glu Thr145 150 155 160Asn Ser
Ser Asn Ile Ser Leu Arg Asn Asn Tyr Met Pro Ser Asn His 165 170
175Gly Phe Gly Ser Ile Ala Ile Val Thr Phe Ser Pro Glu Tyr Ser Phe
180 185 190Arg Phe Asn Asp Asn Ser Met Asn Glu Phe Ile Gln Asp Pro
Ala Leu 195 200 205Thr Leu Met His Glu Leu Ile His Ser Leu His Gly
Leu Tyr Gly Ala 210 215 220Lys Gly Ile Thr Thr Lys Tyr Thr Ile Thr
Gln Lys Gln Asn Pro Leu225 230 235 240Ile Thr Asn Ile Arg Gly Thr
Asn Ile Glu Glu Phe Leu Thr Phe Gly 245 250 255Gly Thr Asp Leu Asn
Ile Ile Thr Ser Ala Gln Ser Asn Asp Ile Tyr 260 265 270Thr Asn Leu
Leu Ala Asp Tyr Lys Lys Ile Ala Ser Lys Leu Ser Lys 275 280 285Val
Gln Val Ser Asn Pro Leu Leu Asn Pro Tyr Lys Asp Val Phe Glu 290 295
300Ala Lys Tyr Gly Leu Asp Lys Asp Ala Ser Gly Ile Tyr Ser Val
Asn305 310 315 320Ile Asn Lys Phe Asn Asp Ile Phe Lys Lys Leu Tyr
Ser Phe Thr Glu 325 330 335Phe Asp Leu Ala Thr Lys Phe Gln Val Lys
Cys Arg Gln Thr Tyr Ile 340 345 350Gly Gln Tyr Lys Tyr Phe Lys Leu
Ser Asn Leu Leu Asn Asp Ser Ile 355 360 365Tyr Asn Ile Ser Glu Gly
Tyr Asn Ile Asn Asn Leu Lys Val Asn Phe 370 375 380Arg Gly Gln Asn
Ala Asn Leu Asn Pro Arg Ile Ile Thr Pro Ile Thr385 390 395 400Gly
Arg Gly Leu Val Lys Lys Ile Ile Arg Phe Cys Lys Asn Ile Val 405 410
415Ser Val Lys Gly Ile Arg Lys Leu Glu His His His His His His 420
425 430
* * * * *